England and Mexico, 1824-25,

"Reprinted from University of Colorado Studies, v. iii, no. 3, Boulder, Colo., June, 1906."

Select statutes and other documents illustrative of the history of the United States 1861-1898;

Pub. in continuation of his Select charters and other documents illustrative of American history, 1606-1775 (New York, 1899) and Select documents illustrative of the history of the United States, 1776-1861 (New York, 1898)

Following the flag. From August, 1861, to November, 1862, with the Army of the Potomac.

Mode of access: Internet.

Histoire des premiers siècles de l'église chrétienne,

Mode of access: Internet.

Confidential correspondence of Gustavus Vasa Fox : assistant secretary of the navy, 1861-1865 /

No more published.

A ballad book, or Popular and romantic ballads and songs current in Annandale and other parts of Scotland. Reprinted from the rare original edition of 1824 [1823].

Mode of access: Internet.

Reise der K. preussischen Gesandtschaft nach Persien, 1860 und 1861, geschildert

Mode of access: Internet.

A catalogue of the highly valuable collection of prints, the property of the late Sir Mark Masterman Sykes ... which ... will be sold by auction by Mr. Sotheby ... March-[December] 1824.

Priced.

Pöytäkirjat pidetyt siinä Suomen neljän säädyn Waliokunnassa, joka Keisarillisen Majesteetin armollisen ilmoitus-säännön mukaan maaliskuun 29 (huhtikuun 10) päiwältä 1861 yhtyi Helsingissä tammikuun 20-maaliskuun 6 päiwinä 1862.

Mode of access: Internet.

Domingues, Ivan. O continente e a ilha. Duas vias da filosofia contemporânea. Sao Paulo: Loyola, 2009. 99 p.

Fil: Karczmarczyk, Pedro. Universidad Nacional de La Plata. Facultad de Humanidades y Ciencias de la Educación. Instituto de Investigaciones en Humanidades y Ciencias Sociales (UNLP-CONICET); Argentina.

Ivan Turgueniev : Una lectura de la transición

Fil: Arce, María Eray. Universidad Nacional de La Plata. Facultad de Humanidades y Ciencias de la Educación; Argentina.

Ranibizumab versus Bevacizumab to treat neovascular age-related macular degeneration:one-year findings from the IVAN Randomized Trial

PURPOSE: To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD). DESIGN: Multicenter, noninferiority factorial trial with equal allocation to groups. The noninferiority limit was 3.5 letters. This trial is registered (ISRCTN92166560). PARTICIPANTS: People >50 years of age with untreated nAMD in the study eye who read =25 letters on the Early Treatment Diabetic Retinopathy Study chart. METHODS: We randomized participants to 4 groups: ranibizumab or bevacizumab, given either every month (continuous) or as needed (discontinuous), with monthly review. MAIN OUTCOME MEASURES: The primary outcome is at 2 years; this paper reports a prespecified interim analysis at 1 year. The primary efficacy and safety outcome measures are distance visual acuity and arteriothrombotic events or heart failure. Other outcome measures are health-related quality of life, contrast sensitivity, near visual acuity, reading index, lesion morphology, serum vascular endothelial growth factor (VEGF) levels, and costs. RESULTS: Between March 27, 2008 and October 15, 2010, we randomized and treated 610 participants. One year after randomization, the comparison between bevacizumab and ranibizumab was inconclusive (bevacizumab minus ranibizumab -1.99 letters, 95% confidence interval [CI], -4.04 to 0.06). Discontinuous treatment was equivalent to continuous treatment (discontinuous minus continuous -0.35 letters; 95% CI, -2.40 to 1.70). Foveal total thickness did not differ by drug, but was 9% less with continuous treatment (geometric mean ratio [GMR], 0.91; 95% CI, 0.86 to 0.97; P = 0.005). Fewer participants receiving bevacizumab had an arteriothrombotic event or heart failure (odds ratio [OR], 0.23; 95% CI, 0.05 to 1.07; P = 0.03). There was no difference between drugs in the proportion experiencing a serious systemic adverse event (OR, 1.35; 95% CI, 0.80 to 2.27; P = 0.25). Serum VEGF was lower with bevacizumab (GMR, 0.47; 95% CI, 0.41 to 0.54; P